The PMPRB protects and informs Canadians by ensuring that the prices of patented medicines sold in Canada are not excessive and by reporting on pharmaceutical trends.
The Annual Report sets out detailed information on the PMPRB’s regulatory activities; patentees’ compliance with the Board’s pricing guidelines; sales and trends of patented drugs in Canada; spending on pharmaceutical R&D, and more.
Find out more…
The PMPRB is seeking to generate an open, informed dialogue with stakeholders and members of the public on areas of the PMPRB’s drug pricing guidelines in need of reform.
Spending by Canadian public drug plans increased by an average of 2.0% in 2013/14, reversing a multi-year trend of low or negative growth.
The PMPRB’s three-year Strategic Plan includes four new strategic objectives, a reinvigorated mission statement, and a vision as to how the organization can work with partners and stakeholders in advancing the common goal of a sustainable health system.
Reducing brand-name prices to generic levels would offer sizable savings in private plans.
This first study in the new NPDUIS private drug plan series explores the evolving generic market in private plans.